Hemophilia a and b recombinant factor replacement therapy japan drug forecast and market analysis to

Hemophilia A and B Recombinant Factor Replacement Therapy Japan Drug Forecast and Market Analysis to 2024 The report " Hemophilia A and B Recombinant Factor Replacement Therapy Japan Drug Forecast and Market Analysis to 2024 ", has been prepared based on an indepth market analysis with inputs from industry experts. Congenital Hemophilia A and B are bleeding disorders that are caused by genetic Xlinked deficiencies in the blood clotting Factors VIII and IX, respectively. Hemophilia manifests as mild, moderate, or severe inability to form clots, depending upon the endogenous levels of circulating factor in an individual patient. The mainstay of treatment for hemophilia is to replace the missing FVIII or FIX, produced using plasmaderived or recombinant methods. Some patients develop inhibitors to FVIII or FIX treatment and need a bypassing agent, such as FVIIa, to resolve bleeds. Patients of hemophilia A or B often require lifelong treatment to prevent and control bleeding episodes, and this therefore represents a lucrative sales opportunity. Japans total market for recombinant hemophilia treatments is projected to grow very modestly. However, the overall prevalence of hemophilia A and B in Japan is expected to decline over the forecast period due to the declining population and birth rate. In addition, GlobalData believes that opportunities for premium pricing will be limited in Japan, further constraining the growth of the Japanese hemophilia market. View Report At: http://www.marketresearchreports.biz/analysis/759743 Scope Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for the top drugs in Japan from 20142024. Analysis of the impact of key events as well the drivers and restraints affecting Japan Hemophilia A and B market. Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B. Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make more informed business decisions from insightful and indepth analysis of drug performance Obtain sales forecast for drugs from 20142024 in Japan. Download Sample copy of this Report @ http://www.marketresearchreports.biz/sample/sample/759743 Table of Content : 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Catalyst 2.2 Related Reports 2.3 Upcoming Related Reports 3 Disease Overview 3.1 Etiology and Pathophysiology 3.1.1 Etiology 3.1.2 Pathophysiology 3.1.3 Prognosis and Quality of Life 3.2 Symptoms 3.2.1 Hemophilia A and B 3.2.2 Inhibitors 4 Disease Management 4.1 Treatment Overview 4.1.1 Hemophilia A and B Diagnosis 4.1.2 Hemophilia A and B Treatment 4.1.3 Diagnosis of Inhibitors 4.1.4 Treatment of Inhibitors 4.2 Japan 4.2.1 Clinical Practice 5 Competitive Assessment 5.1 Overview 5.2 Strategic Competitive Assessment 5.3 Product Profiles Hemophilia A 5.3.1 Advate (Octocog Alfa)

5.3.2 Kogenate FS/Helixate FS (Octocog Alfa) 5.3.3 Xyntha/ReFacto AF (Moroctocog Alfa) 5.3.4 Recombinate (Octocog Alfa) 5.3.5 Eloctate (Efmoroctocog Alfa) 5.3.6 NovoEight (Turoctocog Alfa) 5.3.7 Nuwiq (Simoctocog Alfa) 5.4 Product Profiles Hemophilia B 5.4.1 BeneFIX (Nonacog Alfa) 5.4.2 Alprolix (Eftrenonacog Alfa) 5.4.3 Rixubis (Nonacog Gamma) 5.4.4 IXinity (Trenonacog Alfa) 5.5 Product Profiles Hemophilia A and B with Inhibitors 5.5.1 NovoSeven RT (Eptacog Alfa) 6 Unmet Need and Opportunity 6.1 Overview About us MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries. Contact us: Mr. Nachiket 90 Sate Street, Suite 700 Albany, NY 12207 Tel: +15186181030 USA: Canada Toll Free: 8669974948 Website: http://www.marketresearchreports.biz/ E : sales@marketresearchreports.biz

Turn static files into dynamic content formats.

Create a flipbook

Hemophilia a and b recombinant factor replacement therapy japan drug forecast and market analysis to

Published on Jul 25, 2016

roshani

Congenital Hemophilia A and B are bleeding disorders that are caused by genetic X-linked deficiencies in the blood clotting Factors VIII and IX, respectively. Hemophilia manifests as mild, moderate, or severe inability to form clots, depending upon the endogenous levels of circulating factor in an individual patient. The mainstay of treatment for hemophilia is to replace the missing FVIII or FIX, produced using plasma-derived or recombinant methods. Some patients develop inhibitors to FVIII or FIX treatment and need a bypassing agent, such as FVIIa, to resolve bleeds. Patients of hemophilia A or B often require lifelong treatment to prevent and control bleeding episodes, and this therefore represents a lucrative sales opportunity.